Recently, a number of studies have shown that activation of ARF6 and its downstream signaling is essential for the progression of multiple cancers, and overexpression of ARF6 was observed in several cancers and is associated with poor overall survival, including in pancreatic cancer, melanoma, breast cancer, and lung adenocarcinoma (25, 28–33). Here, ARF6 is linked to lung adenocarcinoma.